No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Eli Lilly & Co shares surged on Wall Street on Thursday after the pharma giant smashed market forecasts with its first-quarter results and upped its full-year guidance, helped by soaring demand for its weight-loss treatments.
The Indiana-based firm, which does business as Lilly, reported a 56% jump in revenues from last year to $19.8bn as demand for Mounjaro and Zepbound soared, even though upside was limited by lower prices. The consensus estimate was just $17.82bn.
Mounjaro, the Type 2 diabetes treatment which is also approved for weight loss outside the US, generated sales of $8.66bn over the first quarter, up 125% year-on-year, with revenues outside the US surging to $4.4bn from $1.2bn. Zepbound sales were up 80% at $4.16bn.
First-quarter earnings per share surged 170% to $8.26, with adjusted EPS up 156% at $8.55, easily topping the $6.97 market forecast.
As a result of the strong performance, the company raised its full-year revenue guidance range to $82bn-85bn, $2bn higher than previous estimates.
Lilly chair and chief executive David Ricks said 2026 got "off to a strong start".
First-quarter highlights included the US FDA approval of Foundayo for adults with obesity, or those overweight with weight-related medical problems.
"A key milestone was the U.S. FDA approval of Foundayo-the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s," Ricks said.
The stock was 8.3% higher at $921.61 by 1517 BST.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.